Peptide Schedule
DihexaSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Dihexa Dosage Calculator

CognitiveInjection/OralResearch~12.7 days half-life

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, also called PNB-0408) is a small peptidomimetic derived from angiotensin IV.

Promotes synaptogenesis and dendritic spine formation in animal modelsReversed cognitive deficits in scopolamine-treated and aged ratsOrally active and blood-brain barrier permeableExtremely metabolically stable compared to native angiotensin IV6 weeks on / 6 weeks off

5mcg · Daily

100500
0.1 units
100 units (1mL)
Concentration
5,000
mcg/mL
Draw Volume
0.001
mL
Syringe Units
0.1
units
Doses / Vial
2000
doses
Very small draw (0.1 units) — difficult to measure accurately. Consider using less BAC water for a more concentrated solution.
Try 0.5mL BAC water for an easier-to-measure draw.

Summary: Add 2mL BAC water to your 10mg vial. Draw to 0.1 units on a U-100 syringe for a 5mcg dose. This vial will last 2000 doses.

Cycle Planner

Oral or Subcutaneous. Typical beginner frequency: daily.

Dihexa Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~12.7 days (IV, rat)
50%25%12.5%100%75%50%25%0%013d25d38d51d63dTime after injectionDose remaining
After 1 half-life (13d): 50% remainsAfter 2 half-lives (25d): 25% remainsAfter 3 half-lives (38d): 12.5% remains
At a 10mcg dose: 50% = 5mcg remaining after 13d. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Dihexa Dosing Protocol

LevelDose / InjectionFrequency
Beginner5mgDaily
Moderate10mgDaily
Aggressive20mgDaily

Note: Angiotensin IV analog. HGF/c-Met activator. Also known as PNB-0408. Preclinical only — no human trials exist. Oral or subcutaneous. Doses in mg range, not mcg like most peptides. Cycle 6 weeks on, 6 weeks off.

About Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, also called PNB-0408) is a small peptidomimetic derived from angiotensin IV. It was developed at Washington State University as a metabolically stable analog designed to cross the blood-brain barrier and activate the hepatocyte growth factor (HGF)/c-Met signaling pathway. In animal models, Dihexa has been shown to promote synaptogenesis — the formation of new functional connections between neurons — at picomolar concentrations. Rat studies demonstrated reversal of scopolamine-induced cognitive deficits and improved spatial memory in aged animals. All existing evidence comes from preclinical animal research. No human clinical trials have been conducted, and the long-term safety profile is unknown. Because Dihexa activates the HGF/c-Met proto-oncogenic pathway, there is a theoretical concern about tumor promotion with sustained use. This compound should be considered strictly experimental.

Frequently Asked Questions